Drug-Resistant Epilepsy. Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
Conditions
Interventions
Intervention 1: Intervention group: Mediterranean Ketogenic diet(MKD)
In the opposite group, which is subjected to the Mediterranean ketogenic diet, extra virgin olive oil is a source of fat, green vegetables and salad as carbohydrates, and fish is a major part of prote
Participants who have undergone the classic ketogenic diet follow a 4:1 and 3:1 ratio of fat to protein and carbohydrates. In the standard 4:1 ratio, 90% of calories come from fats, 6% from proteins,
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: Children from 2-18 years old Patients with drug-resistant epilepsy based on the diagnosis of a pediatric neurologist Minimum use of two anticonvulsant drugs and 1 auxiliary drug without proper response
Exclusion criteria
Exclusion criteria: Coexistence of epilepsy with systemic disease, chronic liver, kidney, and lung disease The patient is suffering from hereditary metabolic diseases in fat metabolism A patient with surgical-focus epilepsy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Cholesterol. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Blood sample (enzymatic method using kit). | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of seizures. Timepoint: before the intervention and 2, 4, 6, 8, 10, 12 weeks after the intervention. Method of measurement: Seizure registration calendar.;Aspartate aminotransferase. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Blood sample (Aspartate aminotransferase kit).;Alanine transaminase. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Blood sample (Alanine transaminase kit).;Serum creatinine. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Blood sample (enzymatic method using kit).;Creatinine in urine. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Urine sample (enzymatic method using kit).;Calcium in urine. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Urine sample (enzymatic method using kit).;Calcium in blood. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Blood sample (enzymatic method using kit).;Uric Acid Serum. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Blood sample (enzymatic method using kit).;Fasting Blood Sugar. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Blood sample (Glucose Oxidase-Peroxidase Assay Protocol).;Insulin Serum. Timepoint: At the study's onset(before the intervention begins) and three months after the intervention began. Method of measurement: Blood sample (enzymatic spectrophotometric method).;Serum Urea Nitrogen. Timepoint: At the | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMotahareh Naghashzadeh
Tehran University of Medical Sciences
Outcome results
None listed